SCHEMBL2478397

SCHEMBL2478397

Cc1cc(F)ccc1CN1C(=O)c2ccccc2C1=O

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.52
CASP3 P42574 1/20 0.51
RPS6KA2 Q15349 2/20 0.49
TGM2 P21980 1/20 0.49
GRM5 P41594 1/20 0.48
ACHE P22303 4/20 0.46
MAPT P10636 1/20 0.46
RECQL P46063 1/20 0.46
RXFP1 Q9HBX9 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26625800 0.84 ACHE (0.61) CASP3RPS6KA2GRM5ACHENPC1
SCHEMBL18669187 0.84 ACHE (0.61) CASP3RPS6KA2GRM5ACHENPC1
SCHEMBL2470168 0.84 MAPK1 (0.57) RPS6KA2TGM2MAPTRECQLRXFP1
SCHEMBL10304915 0.84 CASP3 (0.48) CASP3RPS6KA2TGM2GRM5ACHE
SCHEMBL2578279 0.81 CASP3 (0.51) CASP3RPS6KA2GRM5ACHENPC1
SCHEMBL30136662 0.81 TGM2 (0.49) CASP3RPS6KA2TGM2MAPTRECQL
SCHEMBL18668918 0.81 CASP3 (0.54) CASP3RPS6KA2GRM5ACHERECQL
SCHEMBL18669194 0.81 GAA (0.59) CASP3RPS6KA2GRM5MAPTRECQL
SCHEMBL10304923 0.80 PTGS1 (0.65) CASP3RPS6KA2TGM2MAPTRECQL
SCHEMBL29820186 0.80 PTGS1 (0.65) CASP3RPS6KA2TGM2MAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1787991-B2 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2020-06-24 EP disclosed
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2018-05-31 US disclosed
EP-1787991-B1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICAL (JP) 2011-10-05 EP disclosed
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) 2007-12-20 US disclosed
EP-1787991-A1 PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2007-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE PGA5, ATP6AP1, PPA1 P2RX7 342/4885CASP3 1583/4885RPS6KA2 735/4885
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use PGA5, ATP6AP1, PPA1 P2RX7 342/4885CASP3 1583/4885RPS6KA2 735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.